BridgeBio Pharma (BBIO) Company Report

BridgeBio reported a phenomenal launch of Attruby, ending the last quarter of 2025 at a run rate of approximately $440 million in revenue. The company believes Attruby will be at least a $4 billion product.
The company achieved two positive Phase 3 data sets for Encaleret and BBP-418, which are described as having curative potential.
BridgeBio estimates a de-risked peak sales potential of $6 billion from its current pipeline, including $4 billion for Attruby and $1 billion each for Encaleret and BBP-418. The total peak sales potential for the pipeline is $10 billion, with the remaining $4 billion accounting for infegratinib and other programs.
The Phase 3 readout for infegratinib in achondroplasia is anticipated in Q1 2026. Infegratinib is highlighted as the first oral therapeutic option and a targeted FGFR3 inhibitor, distinguishing it from other treatments by targeting both MAPK and STAT1 pathways.
For infegratinib, a positive efficacy outcome in Phase 3 would be north of 1.5 centimeters per year in annualized height velocity, with the oral formulation being a key driver for adoption, especially for the 60%-70% of the U.S. market that is currently treatment-naive.

1 day ago

Transcript

BridgeBio Highlights Strong Attruby Launch and $10 Billion Pipeline Potential

BBIO

Product Launch

Guidance Update

Revenue Acceleration/Inflection

BridgeBio reported a phenomenal launch of Attruby, achieving a run rate of approximately $440 million in revenue in the last quarter of 2025.
The company projects Attruby to be at least a $4 billion product, contributing to a $6 billion de-risked peak sales potential across its pipeline, with a total pipeline potential of $10 billion.
The phase three readout for infegratinib in achondroplasia is anticipated in Q1 2026, with an expected positive efficacy outcome of above 1.5 centimeters per year in annualized growth velocity.
Infegratinib's oral formulation is highlighted as a key differentiator expected to drive adoption among treatment-naive patients and those switching from injectable therapies.

1 day ago

Transcript

BridgeBio Discusses 2025 Accomplishments, Pipeline Potential, and Financial Position

BBIO

Product Launch

Guidance Update

Revenue Acceleration/Inflection

BridgeBio reported a transformational year in 2025, highlighted by the successful launch of Attruby, which achieved a $440 million revenue run rate last quarter, and two positive Phase 3 data readouts for Encaleret and BBP-418.
The company projects a fully de-risked peak sales potential of $6 billion from its current pipeline, with Attruby contributing $4 billion and Encaleret and BBP-418 each contributing $1 billion. The total pipeline peak sales potential is estimated at $10 billion, including future contributions from infegratinib and other programs.
Regarding infegratinib, the CEO of QED Therapeutics discussed its upcoming Phase 3 readout in Q1 2026 for achondroplasia, highlighting its mechanism as the first oral, targeted FGFR3 inhibitor and the convenience of its oral formulation as a key driver for adoption.
BridgeBio maintains a strong financial position with $650 million in cash and $1.8 billion in debt, of which $1.1-$1.2 billion are deeply in-the-money converts. The company expects its cash burn to remain flat due to increasing Attruby sales, despite plans for multiple new product applications and commercialization efforts.

1 day ago

Transcript

BridgeBio Pharma Discusses Attruby Launch and Pipeline Progress

BBIO

Product Launch

Guidance Update

New Projects/Investments

BridgeBio's Attruby launch is progressing "extremely well," with its share in the first-line setting reaching well into the 20% range as of the Q3 earnings call, and a long-term goal of 30-40%. The company expects fewer selling weeks to impact Q4 2025, but the discontinuation of Vyndaqel is anticipated to be a tailwind primarily in 2026.
For achondroplasia, infigratinib is positioned as a potential first oral option, with phase two data showing "best-in-class efficacy". The company aims for phase three results to show at least 1.5 centimeters per year in change from baseline height velocity or a 0.3 improvement in height Z score.
BridgeBio plans to file New Drug Applications (NDAs) for Encaleret (for ADH1) and BBP-418 (for LGMD2i) in the first half of 2026, with expected launches in Q4 2026 or Q1 2027.
Both Encaleret and BBP-418 demonstrated "tremendous data sets," with Encaleret showing over three-quarters of patients achieving complete normalization of blood and urine calcium. These pipeline assets are expected to be priced in the range of $400,000 to $900,000, aligning with rare disease analogs.

3 days ago

Transcript

BridgeBio Provides Updates on Attruby Performance and Pipeline Progress

BBIO

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Attruby's launch is progressing "extremely well", achieving a first-line market share "well into the 20% range" with a long-term goal of 30-40%. The company emphasizes its clinical differentiation as a "superior stabilizer".
BridgeBio anticipates significant growth in the underdiagnosed ATTR-CM market, with newly diagnosed patients on therapy increasing to at least 3,000 per quarter in the U.S. this year. The discontinuation of Vyndaqel is expected to be a "2026 story" for BridgeBio, potentially aiding in converting some accounts.
The company's pipeline includes infigratinib, a potential first oral option for achondroplasia, with Phase 3 data expected to show a 1.5 cm/year change from baseline and a 0.3 improvement in height Z score.
Additionally, Encaleret (for ADH1) and BBP-418 (for LGMD) have shown "tremendous data sets", with NDA filings anticipated in H1 2026 and launches projected for Q4 2026 or Q1 2027. These rare disease products are expected to be priced between $400,000 and $900,000 annually.

3 days ago

Transcript

BridgeBio Pharma Discusses Attruby Launch Progress, Pipeline Development, and Future Commercialization

BBIO

Product Launch

New Projects/Investments

Guidance Update

BridgeBio Pharma's Attruby launch is performing strongly, with its first-line share now well into the 20% range and a long-term goal of 30-40%. The discontinuation of Vyndaqel is expected to provide a tailwind in 2026.
The company anticipates filing New Drug Applications (NDAs) for Encaleret (ADH1) and BBP-418 (LGMD2i) in the first half of 2026, with launches projected for Q4 2026 or Q1 2027.
BridgeBio is positioning infigratinib as potentially the first oral option for achondroplasia, with Phase 3 data expected to show efficacy comparable to existing treatments, and believes an oral therapy could unlock more than half of the U.S. market.
For Encaleret and BBP-418, pricing is expected to align with rare disease analogs, ranging from $400,000 to $900,000 annually, and the company intends to retain global rights for these and infigratinib.

3 days ago

Transcript

BridgeBio Pharma Discusses Attruby Growth and Key Pipeline Milestones

BBIO

Product Launch

New Projects/Investments

Guidance Update

BridgeBio Pharma's commercial product, Attruby, is experiencing continued growth across patient segments, with expectations to achieve 30-40% market share in an expanding market. The company anticipates this growth to continue, with potential for acceleration in 2026.
The company recently announced positive Phase 3 readouts for its limb-girdle type 2I and ADH1 programs, with NDA submissions planned for early 2026 and subsequent ex-US filings.
BridgeBio expects a Phase 3 readout for infigratinib in achondroplasia in early 2026, with the potential for three approved products by this time next year.
Both LGMD2I and ADH1 are identified as billion-dollar-plus opportunities with no current competition. The achondroplasia program is differentiated as an oral small molecule compared to injectable competitors.

Nov 18, 2025, 4:00 PM

Transcript

BridgeBio Provides Updates on Attruby Performance and Pipeline Milestones

BBIO

Product Launch

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

BridgeBio's commercial product, Attruby, continues to demonstrate growth and gain market share in the frontline setting, with expectations to reach 30-40% market share and continued expansion of the overall market. The company is also generating real-world evidence and conducting additional studies to further differentiate Attruby.
The company reported two successful Phase 3 readouts for its limb-girdle type 2I (LGMD2I) program and its ADH1 program, with NDA submissions planned for early next year. The LGMD2I program is a first-in-class therapy with profound improvements in functional endpoints and is considered a billion-dollar-plus opportunity. The ADH1 program showed remarkable results with 76% of patients normalizing calcium levels and is also seen as a billion-dollar-plus opportunity, with plans to expand into the broader chronic hypoparathyroidism market.
A Phase 3 readout for infigratinib in achondroplasia is expected in early 2026. This oral small molecule is differentiated by directly targeting FGFR3 and its once-daily oral administration, which could be a significant advantage over injectable competitors.
BridgeBio is considering providing financial guidance for Attruby, acknowledging the product's approaching one-year launch anniversary.

Nov 18, 2025, 4:00 PM

Transcript

BridgeBio Pharma Discusses Attruby Performance and Pipeline Progress

BBIO

Guidance Update

Product Launch

Revenue Acceleration/Inflection

BridgeBio Pharma's commercial product, Attruby, continues to demonstrate growth across all major segments and momentum in share growth in the frontline setting, with expectations for continued acceleration in 2026. The company is generating real-world evidence to further differentiate Attruby, which has a strong label including near complete stabilization and 50% reduction in hospitalizations.
The company recently had two successful Phase 3 readouts for its limb-girdle type 2I (LGMD2I) program and ADH1 program, with NDA submissions planned for early 2026.
The LGMD2I program showed a P-value less than 0.0001 on its primary endpoint and profound improvement on functional endpoints like FVC and 100-meter time test. This represents a billion-dollar-plus opportunity with an estimated 7,000 patients in the US and Europe.
For ADH1, the Phase 3 data showed 76% of patients could come off supplements and normalize blood/urine calcium, with 91% normalizing serum PTH levels. This is also viewed as a billion-dollar-plus opportunity, with 3,000-4,000 diagnosed/symptomatic patients eligible for therapy.
Looking ahead, BridgeBio expects a Phase 3 readout for infigratinib in achondroplasia in early 2026. This compound is differentiated as an oral small molecule that targets FGFR3 directly, potentially offering a significant advantage over injectable competitors.

Nov 18, 2025, 4:00 PM

Transcript

BridgeBio Pharma Highlights Strong Attruby Sales and Positive Phase 3 Pipeline Readouts

BBIO

Revenue Acceleration/Inflection

Product Launch

New Projects/Investments

BridgeBio Pharma reported a transformational Q3 with accelerating sales for Attruby and positive Phase 3 readouts for Encaloret and BBP-418.
Attruby's launch is successful, with strong uptake in treatment-naive patients and a goal to capture 30%-40% of the ATTR-CM market. Recent data showed a 59% reduction in ACM and 69% reduction in ACM and first CV event in the variant population. The ATTR-CM market is estimated to be 20-25% diagnosed of 250,000 patients.
The Phase 3 trial for Encaloret in ADH1 showed 76% of patients normalized blood and urine calcium by week 24. The company has identified 3,500 U.S. patients for this condition, representing a potential $1 billion+ market opportunity with pricing expected between $300,000-$500,000.
BBP-418's Phase 3 interim analysis for LGMD2i demonstrated significant clinical improvements, including a 17-24% increase in glycosylated alpha-dystroglycan and an 80% decrease in serum creatine kinase, with improvements in ambulation and pulmonary function. This data may support a traditional full approval for an estimated 2,500 U.S. patients.
Further pipeline catalysts include Phase 3 updates for infigratinib in achondroplasia (early 2026) and hypochondroplasia (later 2026).

Nov 10, 2025, 6:15 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for BridgeBio Pharma.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Neil Kumar say about margins?What are BridgeBio Pharma's strategic priorities?How is BridgeBio Pharma positioned vs competitors?How did BridgeBio Pharma do last quarter?

Let Fintool AI Agent track BridgeBio Pharma's earnings for you

Get instant analysis when filings drop